ACADIA Pharmaceuticals Inc.
ACAD
Peringkat dalam Saham
#4429
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Harga Saham
$20.42
Kapitalisasi Pasar
$3.52B
Perubahan (1 hari)
3.13%
Perubahan (1 tahun)
-2.48%
Negara
US
Perdagangan ACADIA Pharmaceuticals Inc. (ACAD)
Kategori
Healthcare
Rasio P/E untuk ACADIA Pharmaceuticals Inc. (ACAD)
Rasio P/E per October 2026 TTM: 8.56
Menurut laporan keuangan dan harga saham terbaru dari ACADIA Pharmaceuticals Inc., rasio P/E saat ini (TTM) adalah 8.56. Pada akhir 2023, perusahaan memiliki rasio P/E sebesar -83.69.
Riwayat rasio P/E untuk ACADIA Pharmaceuticals Inc. dari 2000 hingga 2026
Rasio P/E di akhir setiap tahun
| Tahun | Rasio P/E | Mengubah |
|---|---|---|
| 2026 (TTM) | 8.56 | -36.29% |
| 2024 | 13.43 | -116.05% |
| 2023 | -83.69 | 602.24% |
| 2022 | -11.92 | -46.59% |
| 2021 | -22.31 | -25.30% |
| 2020 | -29.87 | 11.59% |
| 2019 | -26.77 | 220.64% |
| 2018 | -8.35 | -34.55% |
| 2017 | -12.76 | 3.60% |
| 2016 | -12.31 | -43.56% |
| 2015 | -21.82 | -34.66% |
| 2014 | -33.39 | -40.85% |
| 2013 | -56.45 | 361.28% |
| 2012 | -12.24 | 394.30% |
| 2011 | -2.48 | -180.93% |
| 2010 | 3.06 | -379.17% |
| 2009 | -1.10 | 110.77% |
| 2008 | -0.52 | -92.48% |
| 2007 | -6.91 | 26.87% |
| 2006 | -5.45 | -14.23% |
| 2005 | -6.35 | 134.88% |
| 2004 | -2.70 | 289.92% |
| 2003 | -0.69 | -8.25% |
| 2002 | -0.76 | 34.57% |
| 2001 | -0.56 | -20.12% |
| 2000 | -0.70 | 0.00% |
Rasio P/E untuk perusahaan serupa atau pesaing
| Perusahaan | Rasio P/E | Perbedaan Rasio P/E | Negara |
|---|---|---|---|
| 28.78 | 236.41% |
US
|
|
| -28.36 | -431.46% |
US
|
|
| -24.57 | -387.14% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | 254.50% |
NL
|
Bagaimana cara membaca P/E ratio?
Rasio Harga/Laba (P/E) mengukur hubungan antara harga saham perusahaan dan laba per sahamnya.
P/E yang rendah namun positif menunjukkan perusahaan dengan laba tinggi dibandingkan valuasinya saat ini dan mungkin dianggap undervalued. P/E negatif tinggi (mendekati 0) menunjukkan perusahaan yang mengalami kerugian besar.
Perusahaan dengan P/E di atas 30 atau negatif umumnya dianggap sebagai "saham pertumbuhan", artinya investor mengharapkan pertumbuhan atau keuntungan di masa depan.
Perusahaan dengan P/E positif di bawah 10 dianggap sebagai "saham bernilai", artinya perusahaan sudah sangat menguntungkan dan pertumbuhannya kemungkinan tidak besar.